Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

December 17, 2020

Study Completion Date

December 17, 2020

Conditions
Malaria,FalciparumParasitemiaProtozoan InfectionsParasitic Disease
Interventions
DRUG

Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet

artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h

BIOLOGICAL

PfSPZ-DVI Challenge

3200 P. falciparum Sporozoites by direct venous inoculation (DVI)

Trial Locations (1)

2060

SGS Belgium NV Clinical Pharmacology Unit, Antwerp

All Listed Sponsors
collaborator

SGS Life Sciences, a division of SGS Belgium NV

OTHER

collaborator

Institute of Tropical Medicine, Belgium

OTHER

collaborator

Swiss BioQuant

INDUSTRY

collaborator

PrimeVigilance Ltd., UK

INDUSTRY

collaborator

Sanaria Inc.

INDUSTRY

collaborator

Iqvia Pty Ltd

INDUSTRY

collaborator

FGK Representative Service B.V., The Netherlands

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT04310085 - Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites | Biotech Hunter | Biotech Hunter